[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20071787L - 2-morfolin-4-pyrimidonforbindelse - Google Patents

2-morfolin-4-pyrimidonforbindelse

Info

Publication number
NO20071787L
NO20071787L NO20071787A NO20071787A NO20071787L NO 20071787 L NO20071787 L NO 20071787L NO 20071787 A NO20071787 A NO 20071787A NO 20071787 A NO20071787 A NO 20071787A NO 20071787 L NO20071787 L NO 20071787L
Authority
NO
Norway
Prior art keywords
alkyl
integer
pyrimidone
morpholin
disease
Prior art date
Application number
NO20071787A
Other languages
English (en)
Inventor
Fumiaki Uehara
Shinsuke Hiki
Kenji Fukunaga
Toshiyuki Kohara
Kazutoshi Watanabe
Satoshi Yokoshima
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of NO20071787L publication Critical patent/NO20071787L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelse med formel (I), en optisk aktiv isomer eller et farmasøytisk akseptabelt salt av denne: hvor X representerer CH eller N; R1 representerer et C1-C12-alkyl; R2 representerer et hydrogenatom eller lignende; R' representerer et C1-C6alkyl eller lignende; q er 0 eller et helt tall fra 1 til 7; Y representerer et C1-C6-alkyl eller lignende; p er 0 eller et helt tall fra 1 til 5; R representerer et 2,3-dihydroindolyl eller lignende; som anvendes for preventiv og/eller terapeutisk behandling av en sykdom forårsaket av hyperaktivitet hos T-proteinkinase 1, så som neurodegenerative sykdommer (f.eks. Alzheimers sykdom).
NO20071787A 2004-09-09 2007-04-04 2-morfolin-4-pyrimidonforbindelse NO20071787L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004296926 2004-09-09
PCT/JP2005/017080 WO2006028290A1 (en) 2004-09-09 2005-09-09 2-morpholino-4-pyrimidone compound

Publications (1)

Publication Number Publication Date
NO20071787L true NO20071787L (no) 2007-05-09

Family

ID=35385631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071787A NO20071787L (no) 2004-09-09 2007-04-04 2-morfolin-4-pyrimidonforbindelse

Country Status (17)

Country Link
US (1) US8106045B2 (no)
EP (3) EP2258701A1 (no)
JP (1) JP5060287B2 (no)
KR (1) KR20070058586A (no)
CN (1) CN101035781A (no)
AR (1) AR050865A1 (no)
AU (1) AU2005280885B2 (no)
BR (1) BRPI0515628A (no)
CA (1) CA2578434A1 (no)
EA (1) EA013839B1 (no)
IL (1) IL181732A0 (no)
MX (1) MX2007002807A (no)
NO (1) NO20071787L (no)
NZ (1) NZ554300A (no)
TW (1) TW200621760A (no)
WO (1) WO2006028290A1 (no)
ZA (1) ZA200702266B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200740779A (en) * 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
CN101528729A (zh) * 2006-08-23 2009-09-09 辉瑞产品公司 作为gsk-3抑制剂的嘧啶酮化合物
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
AU2008290329B2 (en) 2007-08-22 2011-12-22 Astrazeneca Ab Cyclopropyl amide derivatives
US8198437B2 (en) 2007-09-14 2012-06-12 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-4-one derivative
DE102008010363A1 (de) * 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
JP5442852B2 (ja) * 2009-08-13 2014-03-12 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
JP5535310B2 (ja) * 2009-08-13 2014-07-02 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
ES2891543T3 (es) 2009-09-04 2022-01-28 Biogen Ma Inc Inhibidores de la tirosina quinasa de Bruton
AU2011218491C1 (en) 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
WO2011143155A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
US8802673B2 (en) * 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CU20130027A7 (es) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
CN104974017B (zh) * 2014-04-09 2017-11-17 上海医药工业研究院 (1r,2s)‑2‑(3,4‑二氟苯基)环丙胺·d‑扁桃酸盐的制备方法
MX2019000884A (es) 2016-07-21 2019-09-04 Biogen Ma Inc Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
CN108299252A (zh) * 2018-04-04 2018-07-20 梯尔希（南京）药物研发有限公司 一种去甲肾上腺素磺酸类代谢物的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
AU2001262150A1 (en) * 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
KR100754596B1 (ko) * 2001-09-21 2007-09-05 미쯔비시 웰 파마 가부시키가이샤 3-치환-4-피리미돈 유도체
AU2002337499B2 (en) * 2001-09-21 2007-08-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
EA009027B1 (ru) 2002-12-16 2007-10-26 Мицубиси Фарма Корпорейшн Производные 3-замещенного-4-пиримидона
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
PL1805164T3 (pl) * 2004-09-29 2011-07-29 Mitsubishi Tanabe Pharma Corp Pochodne 6-(pirydynylo)-4-pirymidonu jako inhibitory kinazy 1 białka tau

Also Published As

Publication number Publication date
US20090124618A1 (en) 2009-05-14
CA2578434A1 (en) 2006-03-16
WO2006028290A1 (en) 2006-03-16
JP2008512347A (ja) 2008-04-24
CN101035781A (zh) 2007-09-12
BRPI0515628A (pt) 2008-03-04
EP2266979A1 (en) 2010-12-29
KR20070058586A (ko) 2007-06-08
EP2258701A1 (en) 2010-12-08
ZA200702266B (en) 2008-09-25
TW200621760A (en) 2006-07-01
EA013839B1 (ru) 2010-08-30
NZ554300A (en) 2009-12-24
AU2005280885B2 (en) 2011-09-22
AR050865A1 (es) 2006-11-29
MX2007002807A (es) 2007-05-16
JP5060287B2 (ja) 2012-10-31
EA200700572A1 (ru) 2007-10-26
EP1789414A1 (en) 2007-05-30
US8106045B2 (en) 2012-01-31
AU2005280885A1 (en) 2006-03-16
IL181732A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
NO20071787L (no) 2-morfolin-4-pyrimidonforbindelse
NO20072214L (no) 6-(pyridinyl)-4-pyrimidonderivater som inhibitorer av tau-proteinkinase-1
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
NO20071314L (no) Peptidiske vasopressinreseptoragonister
SE0302232D0 (sv) Novel Compounds
NO20082496L (no) Pyrazinderivater
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20054331L (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20080025L (no) Pyrazolderivater som CB1 modulatorer
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
NO20076000L (no) Aminosyrederivater
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
NO20076037L (no) Nye tiazolidinoner uten basisk nitrogen, deres fremstilling og anvendelse som farmasoytiske midler
BR0313000A (pt) Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application